Oromucosal Laminating Adhesive for Extended Retention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oromucosal therapeutic systems face challenges in achieving long retention times, sufficient adhesion between layers of differing polarities, and effective drug release without detaching, while avoiding thermal stress and using hydrophilic polymers like Kollidon VA64, which are not suitable for prolonged adhesion.
Innovation Solution
An oromucosal therapeutic system comprising a backing layer with a film-forming polymer, an adhesive layer made of a laminating adhesive mixture of polyvinylpyrrolidone and polyvinylacetate, and an active agent-containing layer with a plasticizer, allowing for prolonged adhesion and controlled drug release without thermal stress.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a backing layer is used to prevent indirect drug delivery via saliva, then drug loss to GI system is reduced, but the system becomes more complex and manufacturing more difficult
Solution Approach 1:
The system is divided into distinct functional layers: a backing layer (water-insoluble polymer) to prevent saliva contact, an adhesive layer (Kollidon VA64) for mucosal attachment, and an active agent-containing layer for drug delivery. This segmentation allows each layer to perform its specific function optimally while maintaining overall system reliability.
Solution Approach 2:
The system combines multiple materials with different properties: water-insoluble polymers for the backing layer to provide barrier function, hydrophilic Kollidon VA64 for adhesive properties, and erodible matrix materials for controlled drug release. This composite structure resolves the contradiction by integrating materials that collectively achieve both reliability and manageable complexity.
2Ease of operation
If hydrophilic polymers like Kollidon VA64 are used in the adhesive layer, then adhesion to mucosa is improved, but retention time is limited to under 20 minutes
Solution Approach 1:
The patent modifies the polymer composition parameters by combining Kollidon VA64 (providing initial adhesion) with water-insoluble polymers like ethyl cellulose or Eudragit E (providing long-term structural integrity). This parameter change in composition allows the system to maintain both good adhesion and extended retention time exceeding 20 minutes.
Solution Approach 2:
The adhesive layer uses a composite of hydrophilic Kollidon VA64 for mucoadhesive properties and water-insoluble polymers for sustained retention. This composite material approach allows the system to overcome the limitation of pure hydrophilic polymers and achieve retention times greater than 20 minutes while maintaining effective mucosal adhesion.
3Ease of manufacture
If repeated coating and drying is used to manufacture multi-layer laminates, then layer adhesion is achieved, but thermolabile actives are subjected to repeated thermal stress
Solution Approach 1:
The patent applies adhesive layers to the backing layer before applying the active agent-containing layer. This preliminary action allows the structural layers to be bonded first, creating a stable base that requires fewer subsequent drying cycles when the thermolabile active is added later, thereby reducing thermal stress exposure.
Solution Approach 2:
The adhesive layer acts as an intermediary between the backing layer and the active agent-containing layer. This intermediary approach allows layers to be joined with fewer drying cycles by using the adhesive's bonding properties, thereby reducing the number of times thermolabile actives are exposed to thermal stress during manufacturing.
4Ease of manufacture
If the active agent-containing layer is made hydrophilic for direct coating with backing layer, then manufacturing is simplified, but the backing layer cannot protect from saliva
Solution Approach 1:
The adhesive layer serves as an intermediary between the hydrophilic active agent-containing layer and the water-insoluble backing layer. This intermediary layer allows the hydrophilic active layer to maintain its solubility and coating simplicity while the water-insoluble backing layer provides the necessary barrier protection from saliva through the adhesive mediation.
Solution Approach 2:
The system uses composite materials where the active agent-containing layer remains hydrophilic for ease of coating and drug release, while the backing layer uses water-insoluble polymers for saliva protection. The adhesive layer combines both hydrophilic and hydrophobic properties to bond these contrasting materials, resolving the contradiction between manufacturing simplicity and protective reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system achieves long retention times of up to 60 minutes, maintains layer adhesion, and provides controlled drug release directly to the mucosa, reducing unintended gastrointestinal delivery and patient discomfort.
Implementation Method 1
an adhesive layer comprising a laminating adhesive and a plasticizer
Implementation Method 2
an adhesive layer comprising a laminating adhesive and a plasticizer
Implementation Method 3
a mucoadhesive layer structure comprising a backing layer, an adhesive layer and an active agent-containing layer
Data Source
AI summary
The present invention relates to oromucosal therapeutic systems comprising a backing layer, an adhesive layer, and an active agent-containing layer, such oromucosal therapeutic systems for use in a method of treatment and/or prophylaxis, processes of manufacture of such oromucosal therapeutic systems as well as adhesive layers and bi-layer laminates for such oromucosal therapeutic systems.